ImmVirX presents clinical and preclinical updates at American Association for Cancer Research (AACR) Annual Meeting
Phase 1a monotherapy trial complete Well tolerated with no dose limiting toxicities Confirmed pathologic complete response in a target lesion in a colorectal cancer patient with no new sites of metastatic lesions approaching two years since commencing treatment Signs of monotherapy activity in 2 of 9 late-stage cancer patients Induction of cell signalling proteins (cytokines/chemokines), […]
ImmVirX and Innovent Expand Collaboration to Investigate IVX037 with TYVYT® in Liver Cancer
Melbourne, Australia 28 April 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to announce it has expanded its clinical trial collaboration and supply agreement with Innovent Biologics, Inc. […]
ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago
Melbourne, Australia 27 March 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April […]
ImmVirX receives $5.1 million R&D Tax Incentive
Melbourne, Australia 15 January 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $5,079,136 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
Phase 1b trial will evaluate IVX037 and Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer Trial open at 4 sites with further sites to open through Q4. Melbourne, Australia 28 October 2024 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted […]
ImmVirX reports on operations for FY24
Melbourne, Australia 1 October 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2024. The principal activity during the financial year was the […]
ImmVirX presents update on Phase 1a/b Clinical Study at Medical Oncology Group of Australia Annual Meeting
Strong recruitment with 14 patients to date – four sites open + more shortly. Well tolerated, no dose-limiting toxicities. Signs of anti-cancer monotherapy activity in 2 of first 10 late-stage colorectal cancer patients evaluable for response. Late-stage colorectal cancer patient with complete response in injected lesion and no new metastatic disease over one year since […]
ImmVirX appoints Dr. Oksana Zdanska as Medical Director
Melbourne, Australia, 16 April 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generationof receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today. Dr. Zdanska is a highly regarded clinical leader with extensive experience […]
ImmVirX and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers
ImmVirX’s Oncolytic Virus IVX037 to be assessed in combination with Innovent’s checkpoint inhibitor TYVYT® in Colorectal, Ovarian and Gastric Cancer to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers Melbourne, Australia 21st February 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients […]
ImmVirX receives $3.77M R&D tax refund for FY23
Melbourne, Australia 12 February 2024 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
